Access to the Latest Clinical Trials

ECHO is proud to have a leading edge research team who provides patients with access to some of the most current clinical trials in the world. One of these trials is for unresectable locally advanced or metastatic colon cancer with AXIN1 or APC mutation.

ECHO recently enrolled the first two patients in the world for this study. 

Both patients had a diagnosis of colorectal cancer. They had progressed through standards chemotherapies and needed an innovative treatment. ECHO was able to offer a genomically based therapy. The mutation targeted by this investigational agent is APC. Adenomatous polyposis coli (APC) is a gene that suppresses tumor growth. If the APC gene is defective, it makes the gene unstable and more susceptible to additional changes that may lead to colon and rectal cancers. The gene mutation is estimated to occur in 80% of sporadic colorectal cancers. 

There is an unmet need for new therapies in colorectal cancer and ECHO is offering clinical trials to assist in the development of new treatments.

For more information on clinical trials, please contact Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.